Transplantation of Autologously Derived Mitochondria Following Ischemia

Extracorporeal Membrane Oxygenation Complication Clinical Trial

Official title:

Transplantation of Autologously Derived Mitochondria for Protection Against Ischemia-reperfusion Injury Following Ischemia in Subjects on ECMO Support

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02851758
• Other study ID #: IRB-P00014558
• Status: Recruiting
• Phase: N/A
• Start date: August 2, 2017
• Est. completion date: June 2025

Study information

• Verified date: January 2023
• Source: Boston Children's Hospital
• Contact: Breanna Piekarski, RN, BSN
• Phone: 617-919-4457
• Email: breanna.piekarski[@]cardio.chboston.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators propose a robust therapeutic intervention to ameliorate myocardial ischemia/ reperfusion injury and significantly decrease morbidity and mortality in patients requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic mitochondria into the ischemic myocardium.

Description:

Autologous mitochondria will be delivered to the ischemic heart muscle in one of two ways, during clinically indicated surgical procedure or during clinically indicated cardiac catheterization.

For surgical re-operation subjects:

After the subject's chest is open, 1-2 6mm biopsies will be collected from the exposed skeletal muscle of the chest wall. The tissue will be processed at bedside to extract the autologous mitochondria. Surgery will proceed as clinically indicated. Prior to closure of the chest, autologous mitochondria will be injected via 5-10 injections of approximately 0.1 mL each to the damaged area (if damaged muscle is local) or via injection into the proximal aorta while cross-clamped for clinically indicated surgery for global distribution of mitochondria via the coronary arteries if there is no evident area of damage. Following completion of surgical maneuvers the mitochondria will be injected into the aorta and the cross-clamp will be removed. If there is global injury but a cross-clamp is not clinically indicated, direct injection into the myocardium will occur throughout the ventricle as previously described. Chest closure will then occur as and if clinically indicated for both techniques.

For catheterization subjects:

Once in the catheterization lab, the temporary chest closure will be removed and 1-2 6 mm biopsies will be collected from the exposed skeletal muscle of the chest wall by the cardiac surgery team. The tissue will be processed at bedside to extract the autologous mitochondria. The catheterization will proceed as clinically indicated. Prior to completion of the procedure (interventional to restore blood flow or hemodynamics), mitochondria will be infused in 5 mL of buffer as conducted in large animal studies (5) via intracoronary infusion followed by a 5 mL flush with normal saline. Total dose of mitochondria will be equal to direct injection subjects, with a larger dilution to allow to infusion via cardiac catheter.

If there is no marked improvement in ventricular function following the injection/infusion of autologous mitochondria and the subject has a clinically indicated procedure in the days following the initial delivery, a second injection/infusion will be completed. At this time the follow up schedule will be reset to Day 0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: June 2025
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria:

• Pediatric cardiology patients under the age of 18 on ECMO

• concerns for ischemic injury on the Cardiac Intensive Care Unit

Exclusion Criteria:

• Known mitochondria disorders

Related Conditions & MeSH terms

• Extracorporeal Membrane Oxygenation Complication
• Ischemia

Intervention

Other:
• autologous mitochondria transplantation
Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium

Locations

Country	Name	City	State
United States	Boston Children's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Boston Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety- Incidence of severe adverse events	Subjects will be SAE free for one week following injection	1 week
Secondary	Efficacy- Improvement in Outcome measures: increased ventricular function on echocardiogram, measured by ejection fraction	Improvement in ventricular function	1 week- 1 month
Secondary	Efficacy- Improvement in Outcome measures: ability to be separated from ECMO support, measured in days since injection	The ability to decannulate from ECMO support	1 week- 1 month